Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL: EVOLVE CLL/SLL Study

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04269902

Study #:
STUDY00160842

Start Date:
Aug 26, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04269902

View Complete Trial Details & Eligibility at ClinicalTrials.gov